{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Blood Cancer Talks","title":"Episode 72. frontMIND Trial in DLBCL with Dr. Charles Herbaux","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/e589e613\"></iframe>","width":"100%","height":180,"duration":2462,"description":"Episode Overview\nFor the second time in two decades, a phase 3 trial has shown a statistically significant improvement over R-CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL). In this episode, Eddie, Raj, and Ashwin sit down with Professor Charles Herbaux to unpack the data, debate the clinical implications, and ask the question that's on every hematologist's mind: is this enough to change practice?\n\nBackground: Setting the Stage for Tafasitamab\nBefore diving into frontMIND, the episode provides context on tafasitamab, a CD19-targeting monoclonal antibody\nL-MIND (Phase 2 — relapsed/refractory DLBCL):\n81 patients with R/R DLBCL\nORR 58%, complete response rate 41%\nEstablished activity of tafasitamab + lenalidomide in the relapsed setting\nhttps://pubmed.ncbi.nlm.nih.gov/32511983/\nFirst-MIND (Phase 1b — frontline DLBCL, IPI 2–5):\n66 patients randomized: tafa-R-CHOP (n=33) vs. tafa-len-R-CHOP (n=33)\nORR: 75.8% vs. 81.8%, respectively\nSerious treatment-emergent adverse events: 42.4% vs. 51.5%\nProvided the signal (and the safety caution) to move to phase 3\nhttps://pubmed.ncbi.nlm.nih.gov/37369099/\n\nThe frontMIND Trial\nDesign: Phase 3, double-blind, placebo-controlled randomized trial\nIntervention: R-CHOP + tafasitamab (12 mg/kg IV days 1, 8, 15 per cycle) + lenalidomide (25 mg/day, days 1–10 per cycle)\nControl: R-CHOP + placebos\nGCSF mandatory (given double-blind design); VTE prophylaxis (heparin or aspirin) mandatory given lenalidomide\nEnrollment: May 2021 – March 2023; 899 patients randomized\nPrimary endpoint: Investigator-assessed progression-free survival (PFS)\nPatient Population:\nAge 18–80; DLBCL or high-grade B-cell lymphoma, IPI 3–5\nMedian age: 65 years\n96% advanced stage; 54% bulky disease; 31% ECOG PS 2; 82% elevated LDH\n55% IPI 3 / aaIPI 2; 43% IPI 4–5 / aaIPI 3\n8% double/triple hit — a high-risk subgroup included despite R-CHOP being the control\nBroad histologic inclusion: transformed lymphoma, grade 3B FL, T-cell/histiocyte-rich LBCL, EBV+...","thumbnail_url":"https://img.transistorcdn.com/sqlYzk0Oxhchi1Lmft_9Md8dG97D7hyy2rwRG7COuc0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMyMDc4LzE2NTcz/MTQxMDUtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}